In today’s global markets there are few new drugs in the pipeline and even fewer blockbuster drugs getting to market. That’s why late phase development and commercialization is a crucial stage in every product life cycle. Although no one knows your product as well as you, now is the time to take a step back and let someone else look at it from an entirely different perspective. It’s the best way to maximize your product’s scientific credibility and brand awareness.

When you’re choosing a clinical research organization (CRO), you need to choose one with extensive late phase pharmaceutical industry experience. One that offers proactive, creative and collaborative late phase study design and execution that appropriately combines your scientific and commercialization objectives – all the while maintaining regulatory compliance. There may be opportunities for your product that you may not even have dreamed of.

Our approach is to create an integrated late phase study management team, consisting of experienced, pharmaceutical industry and clinical development professionals who can design innovative operational strategies for your Phase IIIB/IV studies.

As an added benefit, our late phase clinical teams are supported by Kendle Regulatory Affairs professionals who can guide you through the complex country-specific regulatory environment, as well as providing risk assessments